CompletedPhase 2NCT05020184
Effect of Oral Cimetidine in the Protoporphyrias
Studying Autosomal erythropoietic protoporphyria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Amy K. Dickey, M.D.
- Principal Investigator
- Amy K Dickey, MDMassachusetts General Hospital
- Intervention
- Cimetidine(drug)
- Enrollment
- 26 enrolled
- Eligibility
- 15 years · All sexes
- Timeline
- 2022 – 2025
Study locations (3)
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
- University of Texas Medical Branch, Galveston, Texas, United States
Collaborators
Wake Forest University Health Sciences · The University of Texas Medical Branch, Galveston
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05020184 on ClinicalTrials.govOther trials for Autosomal erythropoietic protoporphyria
Additional recruiting or active studies for the same condition.
See all trials for Autosomal erythropoietic protoporphyria →